Access the world's leading financial data and tools

Subscribe for $2
Overview
Profile

FluoroPharma Medical stock

FPMI
US3438701019

Price

0.00
Today +/-
+0
Today %
+0 %
P

FluoroPharma Medical stock price

%
Weekly
Details

Price

ⓘ

Overview

The Quote Chart provides detailed and dynamic insights into the FluoroPharma Medical stock's performance, showcasing daily, weekly, or monthly aggregated quotes. Users can switch between different time frames to analyze the stock's progression meticulously and make informed investment decisions.

Intraday Feature

The intraday feature provides real-time data, allowing investors to view the FluoroPharma Medical stock’s price fluctuations within the trading day, facilitating timely and strategic investment decisions.

Total Return and Relative Price Change

View the total return of the FluoroPharma Medical stock to gauge its profitability over time. The relative price change, based on the first quote available in the selected timeframe, offers insights into the stock’s performance, assisting in evaluating its investment potential.

Interpretation and Investment

Utilize the comprehensive data presented in the Quote Chart to analyze FluoroPharma Medical's market trends, price movements, and potential returns. Make informed investment choices by comparing different time frames and evaluating intraday data for optimized portfolio management.

FluoroPharma Medical Stock Price History

DateFluoroPharma Medical Price
10/23/20240.00 undefined

FluoroPharma Medical Revenue, EBIT, Net Income

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Revenue
EBIT
Net Income
Details

Revenue, EBIT and Profit

ⓘ

Understanding Revenue, EBIT, and Income

Gain insights into FluoroPharma Medical, a comprehensive overview of its financial performance can be obtained by analyzing the Revenue, EBIT, and Income chart. Revenue represents the total income generated by FluoroPharma Medical from its primary operations, showcasing the company’s ability to attract and retain clients. EBIT, or Earnings Before Interest and Taxes, indicates the company’s operational profitability, free from the influence of tax and interest expenses. The Income section reflects FluoroPharma Medical’s net earnings, an ultimate measure of its financial health and profitability.

Yearly Analysis and Comparisons

Observe the yearly bars to understand the annual performance and growth of FluoroPharma Medical. Compare the Revenue, EBIT, and Income to evaluate the company’s efficiency and profitability. A higher EBIT compared to the previous year suggests an improvement in operational efficiency. Likewise, an increase in Income indicates enhanced overall profitability. Analyzing the year-to-year comparison assists investors in understanding the company’s growth trajectory and operational efficiency.

Utilizing Expectations for Investment

The expected values for the forthcoming years offer investors a glimpse into FluoroPharma Medical’s anticipated financial performance. Analyzing these projections alongside historical data aids in making informed investment decisions. Investors can gauge the potential risks and returns, aligning their investment strategies accordingly to optimize profitability and mitigate risks.

Investment Insights

Leveraging the comparison between Revenue and EBIT helps in assessing FluoroPharma Medical’s operational efficiency, while the Revenue and Income comparison reveals the net profitability after accounting for all expenses. Investors can derive valuable insights by meticulously analyzing these financial parameters, laying the foundation for strategic investment decisions aimed at capitalizing on FluoroPharma Medical’s growth potential.

FluoroPharma Medical Revenue, EBIT and net profit per share

DateFluoroPharma Medical RevenueFluoroPharma Medical EBITFluoroPharma Medical Net Income
20160 undefined-2.2 M undefined-2.57 M undefined
20150 undefined-3.19 M undefined-3.74 M undefined
20140 undefined-5.17 M undefined-4.69 M undefined
20130 undefined-4.36 M undefined-7.28 M undefined
20120 undefined-4.15 M undefined-4.18 M undefined
20110 undefined-3.27 M undefined-4.24 M undefined
20100 undefined-890,000 undefined-950,000 undefined
20090 undefined-20,000 undefined-20,000 undefined
2008170,000 undefined-10,000 undefined-20,000 undefined
2007110,000 undefined-70,000 undefined-70,000 undefined

FluoroPharma Medical Income Statement, Balance Sheet, Cash Flow Statement

  • Simple

  • Expanded

  • Income Statement

  • Balance Sheet

  • Cashflow

 
REVENUE (M)REVENUE GROWTH (%)GROSS MARGIN (%)GROSS INCOME (M)NET INCOME (M)NET INCOME GROWTH (%)SHARES (M)DOCUMENTS
2007200820092010201120122013201420152016
0000000000
----------
----------
0000000000
0000-4-4-7-4-3-2
------75.00-42.86-25.00-33.33
10.54111112.7117.7322.6424.3728.6430.0433.56
----------
Details

Keystats

ⓘ

Revenue and Growth

The FluoroPharma Medical Revenue and Revenue Growth are pivotal to understanding the company's financial health and operational efficiency. A consistent increase in revenue indicates a company’s ability to effectively market and sell its products or services, while the revenue growth percentage offers insights into the pace at which the company is expanding over the years.

Gross Margin

The Gross Margin is a crucial metric that showcases the percentage of revenue exceeding the cost of goods sold (COGS). A higher gross margin is indicative of a company’s efficiency in controlling its production costs, thereby promising potential profitability and financial stability.

EBIT and EBIT Margin

EBIT (Earnings Before Interest and Taxes) and EBIT Margin offer deep insights into a company’s profitability, excluding the impacts of interest and taxes. Investors often assess these metrics to gauge the operational efficiency and inherent profitability of a business, separate from its financial structure and tax environment.

Income and Growth

Net Income and its subsequent growth are quintessential for investors looking to understand a company’s profitability. Consistent income growth underscores a company’s ability to enhance its profitability over time, reflecting operational efficiency, strategic competitiveness, and financial health.

Shares Outstanding

Shares outstanding refer to the total number of shares a company has issued. It's instrumental in calculating key metrics like Earnings Per Share (EPS) which is pivotal for investors to evaluate a company’s profitability on a per-share basis, offering a more granular view of financial health and valuation.

Interpreting Year to Year Comparison

Comparing yearly data allows investors to identify trends, assess the company’s growth, and anticipate potential future performance. Analyzing how metrics like revenue, income, and margins change year over year can provide valuable insights into the company’s operational efficiency, competitiveness, and overall financial health.

Expectations and Predictions

Investors often juxtapose the current and past financial data with the market’s expectations. This comparison aids in assessing whether the FluoroPharma Medical is performing as anticipated, underperforming or outperforming the market predictions, providing pivotal data for investment decisions.

 
ASSETSCASH BALANCE (M)RECEIVABLES (k)OTHER REC. (M)INVENTORIES (k)OTHER CURRENT LIAB. (k)CURRENT ASSETS (M)TANGIBLE ASSETS (k)LONG-T. INVEST. (M)LONG-T. REC. (M)INTANGIBLE ASSETS (k)GOODWILL (M)OTHER NON-CURRENT ASSETS (M)NON-CURRENT ASSETS (k)TOTAL ASSETS (M)LIABILITIESCOMMON STOCK (k)ADDITIONAL PAID-IN CAPITAL (M)RETAINED EARNINGS (M)OTHER EQUITY (M)UNREAL. GAINS/LOSSES (M)EQUITY (M)LIABILITIES (M)PROVISIONS (M)OTHER SHORT-TERM LIAB. (M)SHORT-TERM DEBTS (M)LONG-TERM DEBT PORTION (M)SHORT-TERM REC. (M)LONG-T. LIAB. (k)DEFERRED TAXES (M)OTHER LIAB. (M)LONG-T. LIABILITIES (k)DEBT (M)TOTAL CAPITAL (M)
2007200820092010201120122013201420152016
                   
0.01000.013.271.31.780.290.290.02
10000000000
0000000000
10000000000
0002050.2977.3252.96158.85218.1623.06
0.03000.033.321.381.830.450.510.05
100030169.81176.8935.4311.7311.057.42
0000000000
0000000000
0006061.1655.2549.34357.54318.55279.55
0000000000
0000000000
100090230.97232.1484.77369.27329.6286.97
0.04000.123.551.611.920.820.840.33
                   
1010101024.2426.4633.7635.8538.4439.47
0.050.050.056.5415.8518.2423.0824.0324.7124.96
-0.07-0.09-0.11-8.47-12.71-16.89-24.17-28.87-32.6-35.18
0000000000
0000000000
-0.01-0.03-0.05-1.923.171.38-1.06-4.8-7.86-10.18
0.01000.840.340.140.231.061.271.45
00.010.010.650.040.101.070.460.89
0000002.741.352.622.35
0.030.030.040.540002.124.355.82
0000000000
0.040.040.052.030.380.242.975.628.710.51
10000000000
0000000000
0000000000
10000000000
0.050.040.052.030.380.242.975.628.710.51
0.040.0100.113.551.611.920.820.840.33
Details

Balance Sheet

ⓘ

Understanding the Balance Sheet

The balance sheet of FluoroPharma Medical provides a detailed financial snapshot, revealing the company's assets, liabilities, and equity at a specific point in time. Analyzing these components is crucial for investors looking to understand FluoroPharma Medical's financial health and stability.

Assets

FluoroPharma Medical's assets represent everything the company owns or controls that has monetary value. These are categorized into current and non-current assets, offering insights into the company's liquidity and long-term investments.

Liabilities

Liabilities are obligations that FluoroPharma Medical must settle in the future. Analyzing the ratio of liabilities to assets provides insights into the company's financial leverage and risk exposure.

Equity

Equity refers to the residual interest in the assets of FluoroPharma Medical after deducting liabilities. It represents the owners’ claim on the company’s assets and earnings.

Year-to-Year Analysis

Comparing balance sheet figures year-to-year allows investors to identify trends, growth patterns, and potential financial risks, facilitating informed investment decisions.

Interpreting the Data

Detailed analysis of assets, liabilities, and equity can provide investors with comprehensive insights into FluoroPharma Medical's financial standing, aiding in investment evaluations and risk assessments.

 
NET INCOME (M)DEPRECIATION (M)DEFERRED TAXES (M)CHANGES IN WORKING CAPITAL (k)NON-CASH ITEM (M)PAID INTEREST (M)PAID TAXES (M)NET CASH FLOW FROM OPERATING ACTIVITIES (M)CAPITAL EXPENDITURES (M)CASH FLOW FROM INVESTING ACTIVITIES (k)CASH FLOW FROM OTHER INVESTING ACTIVITIES (k)INTEREST INCOME AND EXPENSES (M)NET DEBT CHANGE (M)NET CHANGE IN EQUITY (M)CASH FLOW FROM FINANCING ACTIVITIES (M)CASH FLOW FROM OTHER FINANCING ACTIVITIES ()TOTAL DIVIDENDS PAID (M)NET CHANGE IN CASH FLOW (M)FREE CASH FLOW (M)SHARE-BASED COMPENSATION (M)
2007200820092010201120122013201420152016
0000-3-4-5-4-3-2
0000000000
0000000000
00000001,00001,000
0000102000
0000000000
0000000000
0000-2-3-3-3-20
0000000000
0000001,000000
0000001,000000
0000000000
0000000220
0000511000
0000511220
----------
0000000000
00003-10000
-0.080-0.01-0.48-2.47-3.32-3.34-3.68-2.68-0.88
0000000000

FluoroPharma Medical stock margins

The FluoroPharma Medical margin analysis displays the gross margin, EBIT margin, as well as the profit margin of FluoroPharma Medical. The EBIT margin (EBIT/sales) indicates the percentage of sales that remains as operating profit. The profit margin shows the percentage of sales that remains for FluoroPharma Medical.

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Gross margin
EBIT margin
Profit margin
Details

Margin

ⓘ

Understanding Gross Margin

The gross margin, expressed as a percentage, delineates the gross profit made from the FluoroPharma Medical's sales revenue. A higher gross margin percentage indicates that the FluoroPharma Medical retains more revenue after accounting for the costs of goods sold. Investors use this metric to gauge financial health and operational efficiency, as well as to compare it with competitors and industry averages.

EBIT Margin Analysis

EBIT margin represents the FluoroPharma Medical's earnings before interest and taxes. Analyzing the EBIT margin over different years provides insights into the operational profitability and efficiency, excluding the effects of financial leverage and tax structure. A growing EBIT margin over the years signifies improving operational performance.

Revenue Margin Insights

The revenue margin demonstrates the FluoroPharma Medical's total revenue generated. When comparing the revenue margin year over year, investors can gauge the FluoroPharma Medical's growth and market expansion. It is essential to compare the revenue margin with the gross and EBIT margins to understand the cost and profit structures better.

Interpreting Expectations

The expected values for gross, EBIT, and revenue margins provide future financial outlook of the FluoroPharma Medical. Investors should compare these expectations with historical data to understand potential growth and risk factors. It is crucial to consider the underlying assumptions and methodologies used in projecting these expected values to make informed investment decisions.

Comparative Analysis

Comparing the gross, EBIT, and revenue margins, both yearly and over multiple years, enables investors to perform a comprehensive analysis of the FluoroPharma Medical's financial health and growth prospects. Evaluating the trends and patterns in these margins helps in identifying strengths, weaknesses, and potential investment opportunities.

FluoroPharma Medical Margin History

FluoroPharma Medical Gross marginFluoroPharma Medical Profit marginFluoroPharma Medical EBIT marginFluoroPharma Medical Profit margin
201688.24 %0 %0 %
201588.24 %0 %0 %
201488.24 %0 %0 %
201388.24 %0 %0 %
201288.24 %0 %0 %
201188.24 %0 %0 %
201088.24 %0 %0 %
200988.24 %0 %0 %
200888.24 %-5.88 %-11.76 %
2007100 %-63.64 %-63.64 %

FluoroPharma Medical Stock Sales Revenue, EBIT, Earnings per Share

The FluoroPharma Medical earnings per share therefore indicates how much revenue FluoroPharma Medical has generated per share in a given period. The earnings before interest and taxes per share shows how much of the operating profit corresponds to each share. The earnings per share indicates how much of the profit belongs to each share.

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Sales per Share
EBIT per share
Earnings per Share
Details

Revenue, EBIT and Earnings per share

ⓘ

Revenue Per Share

Revenue per share represents the total revenue FluoroPharma Medical earns, divided by the number of outstanding shares. It is a crucial metric as it reflects the company's ability to generate sales and signifies growth and expansion potential. Comparing yearly revenue per share allows investors to analyze the consistency in a company’s earnings and predict future trends.

EBIT Per Share

EBIT per share indicates FluoroPharma Medical's earning before interest and taxes, offering insights into operational profitability excluding the effects of capital structure and tax rates. It can be juxtaposed against revenue per share to gauge the efficiency in converting sales into profits. A consistent increase in EBIT per share over the years underscores operational efficiency and profitability.

Income Per Share

Income per share, or earnings per share (EPS), reveals the portion of FluoroPharma Medical’s profit allocated to each share of common stock. It’s instrumental in evaluating the profitability and financial health. By comparing it with revenue and EBIT per share, investors discern how effectively a firm translates sales and operational profits into net income.

Expected Values

Expected values are projections of revenue, EBIT, and income per share for forthcoming years. These anticipations, rooted in historical data and market analysis, aid investors in strategizing their investments, evaluating FluoroPharma Medical's prospective performance, and estimating future stock prices. However, it’s pivotal to consider market volatilities and uncertainties that can influence these projections.

FluoroPharma Medical Revenue, EBIT and net profit per share

DateFluoroPharma Medical Sales per ShareFluoroPharma Medical EBIT per shareFluoroPharma Medical Earnings per Share
20160 undefined-0.07 undefined-0.08 undefined
20150 undefined-0.11 undefined-0.12 undefined
20140 undefined-0.18 undefined-0.16 undefined
20130 undefined-0.18 undefined-0.3 undefined
20120 undefined-0.18 undefined-0.18 undefined
20110 undefined-0.18 undefined-0.24 undefined
20100 undefined-0.07 undefined-0.07 undefined
20090 undefined-0 undefined-0 undefined
20080.02 undefined-0 undefined-0 undefined
20070.01 undefined-0.01 undefined-0.01 undefined

FluoroPharma Medical business model

FluoroPharma Medical Inc is an innovative company from the USA that specializes in molecular imaging. It was founded in 2003 and is based in Boston, Massachusetts. The company's goal is to improve the diagnosis and treatment of cardiovascular and cancer diseases. The business model of FluoroPharma Medical is based on the development of radioactive tracers that are used in conjunction with imaging techniques such as PET (Positron Emission Tomography). These tracers are typically administered in the form of radiopharmaceuticals and allow real-time tracking of metabolic processes in the body of patients. The information obtained is used by doctors to make diagnoses and optimize treatment. FluoroPharma Medical specializes in the development of tracers specifically for cardiovascular and cancer diseases. These include the tracer BFPET (up to 3 hours), which is used for the diagnosis of coronary heart disease, and the tracer CardioPET (up to 3 hours), which is used for the diagnosis of cardiovascular diseases. In addition, the company is working on other tracers that are intended for the diagnosis of various types of cancer, such as prostate cancer, breast cancer, and lung cancer. FluoroPharma Medical is divided into different divisions to better organize its activities. The Research and Development division is responsible for the development of new tracers and conducting clinical studies. The Production division is responsible for the manufacturing and distribution of radiopharmaceuticals. Marketing and distribution are handled by the Sales and Marketing division, which works closely with doctors and hospitals. The products of FluoroPharma Medical are currently still in the development phase and not commercially available. However, the company is working closely with various universities and medical facilities to test its tracers in clinical trials. The aim is to demonstrate the effectiveness and safety of the tracers and obtain approval from the FDA (Food and Drug Administration). FluoroPharma Medical has established itself as a pioneer in the field of molecular imaging and is committed to further improving the diagnosis and treatment of cardiovascular and cancer diseases. With its innovative tracers and focus on clinical practice, the company has the potential to significantly improve the medical care of patients in the future. FluoroPharma Medical is one of the most popular companies on Eulerpool.com.

FluoroPharma Medical SWOT Analysis

Strengths

FluoroPharma Medical Inc possesses several key strengths that contribute to its competitive advantage in the market. These include:

  • Advanced Technology: FluoroPharma utilizes cutting-edge technology to develop novel molecular imaging agents, providing accurate and precise diagnostic tools for medical professionals.
  • Diverse Product Portfolio: The company offers a wide range of innovative diagnostic imaging agents, catering to various medical needs and enhancing its market presence.
  • Strong Intellectual Property: FluoroPharma holds a robust portfolio of patents and intellectual property rights, safeguarding its research and development efforts and providing a barrier to entry for potential competitors.
  • Strategic Partnerships: The company has established strategic collaborations with leading healthcare organizations, enabling access to resources, expertise, and market opportunities.
  • Experienced Management Team: FluoroPharma is led by a talented and experienced management team with a proven track record in the medical technology industry, fostering innovation and driving growth.

Weaknesses

FluoroPharma Medical Inc faces certain weaknesses that may hinder its performance and market position. These weaknesses include:

  • Financial Dependency: The company may heavily rely on external funding to support its research and development activities, posing a potential risk of limited financial resources.
  • Regulatory Challenges: FluoroPharma operates within a highly regulated industry, and delays or obstacles in obtaining regulatory approvals for its products can impact market entry timelines and competitiveness.
  • Competition: The medical imaging market is highly competitive, with well-established players and constant technological advancements. This poses challenges for FluoroPharma to differentiate and capture market share.

Opportunities

FluoroPharma Medical Inc can leverage several opportunities to enhance its market position and growth prospects. These opportunities include:

  • Increasing Demand for Molecular Imaging: The rising prevalence of chronic diseases and the need for early and accurate diagnosis create a growing market demand for effective molecular imaging agents, which FluoroPharma can capitalize on.
  • Emerging Markets: Expanding into emerging markets presents an opportunity for FluoroPharma to access new customer bases, drive revenue growth, and establish a global presence.
  • Product Pipeline Expansion: Continuously investing in research and development can lead to the development of new and improved diagnostic imaging agents, enabling the company to address unmet medical needs and gain a competitive edge.

Threats

FluoroPharma Medical Inc encounters several threats that may pose challenges to its success and profitability. These threats include:

  • Market Volatility: The medical technology industry is subject to rapid changes, shifting customer preferences, and economic fluctuations, which may impact product demand and financial stability.
  • Regulatory and Legal Risks: Compliance with complex regulations and potential legal disputes can lead to delays, increased costs, and reputational damage.
  • Technological Changes: Advancements in imaging technologies and the emergence of alternative diagnostic methods may render FluoroPharma's products obsolete or less competitive.
  • Price Pressure: Pricing pressures from healthcare providers, insurers, and government healthcare policies can significantly impact the company's profitability and pricing strategies.
LIMITED TIME OFFER

The World’s Best Investors Are On Eulerpool

Subscribe for $2

FluoroPharma Medical Eulerpool Fair Value

Details

Fair Value

ⓘ

Understanding Fair Value

The fair value of a stock provides insights into whether the stock is currently undervalued or overvalued. It is calculated based on profit, revenue, or dividends and offers a comprehensive perspective of the stock’s intrinsic value.

Income-Based Fair Value

This is calculated by multiplying the earnings per share by the average P/E ratio of the selected past years for smoothing. If the fair value is higher than the current market price, it suggests that the stock is undervalued.

Example 2022

Fair Value Profit 2022 = Earnings per Share 2022 / Average P/E Ratio 2019 - 2021 (3 Years Smoothing)

Revenue-Based Fair Value

It is derived by multiplying the revenue per share by the average price-to-sales ratio of the selected past years for smoothing. An undervalued stock is identified if the fair value exceeds the ongoing market price.

Example 2022

Fair Value Revenue 2022 = Revenue per Share 2022 / Average PSR 2019 - 2021 (3 Years Smoothing)

Dividend-Based Fair Value

This value is determined by dividing the dividend per share by the average dividend yield of the selected past years for smoothing. A higher fair value than the market price indicates an undervalued stock.

Example 2022

Fair Value Dividend 2022 = Dividend per Share 2022 * Average Dividend Yield 2019 - 2021 (3 Years Smoothing)

Expectations and Forecasts

Future expectations provide potential trajectories for stock prices and aid investors in decision-making. The expected values are forecasted figures of fair value, taking into account the growth or decline trends of profit, revenue, or dividend.

Comparative Analysis

Comparing the fair value based on profit, revenue, and dividend provides a holistic overview of the stock’s financial health. Observing the annual and per-annual variations contributes to understanding the consistency and reliability of stock performance.

FluoroPharma Medical historical P/E ratio, EBIT multiple, and P/S ratio

LIMITED TIME OFFER

The World’s Best Investors Are On Eulerpool

Subscribe for $2

FluoroPharma Medical shares outstanding

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Number of stocks
Details

Revenue, EBIT and Earnings per share

ⓘ

Revenue Per Share

Revenue per share represents the total revenue FluoroPharma Medical earns, divided by the number of outstanding shares. It is a crucial metric as it reflects the company's ability to generate sales and signifies growth and expansion potential. Comparing yearly revenue per share allows investors to analyze the consistency in a company’s earnings and predict future trends.

EBIT Per Share

EBIT per share indicates FluoroPharma Medical's earning before interest and taxes, offering insights into operational profitability excluding the effects of capital structure and tax rates. It can be juxtaposed against revenue per share to gauge the efficiency in converting sales into profits. A consistent increase in EBIT per share over the years underscores operational efficiency and profitability.

Income Per Share

Income per share, or earnings per share (EPS), reveals the portion of FluoroPharma Medical’s profit allocated to each share of common stock. It’s instrumental in evaluating the profitability and financial health. By comparing it with revenue and EBIT per share, investors discern how effectively a firm translates sales and operational profits into net income.

Expected Values

Expected values are projections of revenue, EBIT, and income per share for forthcoming years. These anticipations, rooted in historical data and market analysis, aid investors in strategizing their investments, evaluating FluoroPharma Medical's prospective performance, and estimating future stock prices. However, it’s pivotal to consider market volatilities and uncertainties that can influence these projections.

LIMITED TIME OFFER

The World’s Best Investors Are On Eulerpool

Subscribe for $2
Unfortunately, there are currently no price targets and forecasts available for FluoroPharma Medical.

FluoroPharma Medical latest earnings and earnings surprises

DateEPS EstimateEPS ActualQuarterly report
9/30/2014-0.05 -0.04  (21.57 %)2014 Q3
6/30/2014-0.05 -0.08  (-56.86 %)2014 Q2
3/31/2014-0.07 -0.05  (29.97 %)2014 Q1
12/31/2013-0.05 -0.11  (-115.69 %)2013 Q4
9/30/2013-0.05 -0.1  (-96.08 %)2013 Q3
6/30/2013-0.06 -0.05  (10.87 %)2013 Q2
3/31/2013-0.06 -0.04  (34.64 %)2013 Q1
12/31/2012-0.05 -0.06  (-17.65 %)2012 Q4
9/30/2012-0.04 -0.05  (-22.55 %)2012 Q3
6/30/2012-0.05 -0.04  (21.57 %)2012 Q2
1

FluoroPharma Medical shareholders

%
Name
Stocks
Change
Date
0 % Williams Jones Wealth Management LLC0-117,6473/31/2023
1

Most common questions regarding FluoroPharma Medical

What values and corporate philosophy does FluoroPharma Medical represent?

FluoroPharma Medical Inc represents values of innovation, dedication, and commitment to improving healthcare through cutting-edge molecular imaging agents. With a strong corporate philosophy centered around research and development of novel imaging agents, FluoroPharma Medical Inc aims to provide physicians and patients with advanced diagnostic tools for better disease detection and treatment. By continuously seeking innovative solutions and leveraging its expertise in molecular imaging, FluoroPharma Medical Inc strives to enhance patient care and contribute to the advancement of personalized medicine.

In which countries and regions is FluoroPharma Medical primarily present?

FluoroPharma Medical Inc is primarily present in the United States.

What significant milestones has the company FluoroPharma Medical achieved?

FluoroPharma Medical Inc has achieved several significant milestones. The company successfully completed a Phase II clinical trial for CardioPET, an imaging agent used to detect cardiac ischemia. Additionally, FluoroPharma received clearance from the U.S. FDA to begin Phase II trials for BFPET, a diagnostic imaging agent for Alzheimer's disease. Furthermore, the company entered into a strategic collaboration with Advanced Accelerator Applications to develop and commercialize cardiovascular imaging agents. These achievements demonstrate FluoroPharma's commitment to advancing innovative imaging technologies for improved patient care.

What is the history and background of the company FluoroPharma Medical?

FluoroPharma Medical Inc is a specialized molecular imaging company that develops pharmaceuticals to enhance patient care. Founded in 2003, the company focuses on the research and development of innovative diagnostic imaging agents with specific applications in cardiology, oncology, and neurology. FluoroPharma's cutting-edge technologies enable medical professionals to accurately identify and assess various medical conditions and diseases. With a strong commitment to advancing personalized medicine, FluoroPharma Medical Inc utilizes positron emission tomography (PET) imaging to provide precise diagnostic information, aiding in early detection and effective treatment planning. This commitment to groundbreaking molecular imaging solutions makes FluoroPharma Medical Inc a trusted leader in the field.

Who are the main competitors of FluoroPharma Medical in the market?

The main competitors of FluoroPharma Medical Inc in the market are Cardinal Health, Bracco Imaging, and GE Healthcare.

In which industries is FluoroPharma Medical primarily active?

FluoroPharma Medical Inc is primarily active in the pharmaceutical and healthcare industries.

What is the business model of FluoroPharma Medical?

The business model of FluoroPharma Medical Inc is centered around developing and commercializing molecular imaging pharmaceuticals for use in the field of nuclear medicine. Through its advanced technology platform, the company aims to improve patient diagnosis and treatment. FluoroPharma Medical Inc focuses on developing novel radiopharmaceuticals for positron emission tomography (PET) imaging, which enable non-invasive visualization and quantification of biological processes in the body. By providing innovative diagnostic solutions, the company contributes to enhancing the efficiency and precision of medical procedures, leading to better patient outcomes.

What is the P/E ratio of FluoroPharma Medical 2024?

The P/E ratio cannot be calculated for FluoroPharma Medical at the moment.

What is the P/S ratio of FluoroPharma Medical 2024?

The P/S cannot be calculated for FluoroPharma Medical currently.

What is the Quality Investing of FluoroPharma Medical?

The Quality Investing for FluoroPharma Medical is 3/10.

What is the revenue of FluoroPharma Medical 2024?

The revenue cannot currently be calculated for FluoroPharma Medical.

How high is the profit of FluoroPharma Medical 2024?

The profit cannot currently be calculated for FluoroPharma Medical.

What is the business model of FluoroPharma Medical

FluoroPharma Medical Inc is a company specialized in developing innovative molecular imaging solutions for the diagnosis of cardiovascular diseases and cancer. Its business model aims to develop and distribute these innovative drugs and technologies to medical institutions, research facilities, and pharmaceutical companies worldwide. One of FluoroPharma's core areas is the conception and development of molecular imaging solutions. These solutions allow for the early detection of diseases before they manifest and lead to serious health complications. The company manufactures its imaging solutions in collaboration with leading scientists, clinical researchers, and experts in biomedical imaging. Another core area of FluoroPharma is clinical research and development. The company continuously conducts clinical studies to evaluate the efficacy and safety of its products. It employs highly qualified medical professionals involved in the development and execution of clinical studies. This ensures that FluoroPharma's products meet the highest standards and deliver the best possible results to patients. FluoroPharma has a portfolio of innovative molecular imaging solutions for the diagnosis of cardiovascular diseases and cancer. The company develops and sells both therapeutic and diagnostic imaging solutions. The diagnostic portfolio includes PET imaging solutions such as CardioPET, the earliest PET imaging solution for patients. The company also offers BFPET, an innovative proprietary PET imaging solution for the diagnosis of breast cancer. FluoroPharma also manufactures therapeutic imaging agents used for targeted diagnosis and treatment of diseases. One such imaging agent is AZPET, an innovative PET imaging agent for the diagnosis and treatment of prostate cancer administered in conjunction with targeted therapy. FluoroPharma Medical has achieved broad market presence through partnerships and strategic alliances with research institutions and pharmaceutical companies in the United States and Europe. The company has an experienced and dedicated team of experts in all areas - from research and development to sales strategy. This expertise enables FluoroPharma to be successful in the market and maintain a leading position in the field of molecular imaging solutions. Overall, we can say that FluoroPharma Medical Inc. is an innovative company that offers a wide range of molecular imaging solutions and has a deep understanding of the needs of patients, physicians, and pharmaceuticals. Through collaboration with leading scientists and experts, the company strives to develop sophisticated products and services to improve patients' lives and promote health.

What is the FluoroPharma Medical dividend?

FluoroPharma Medical pays a dividend of 0 USD distributed over payouts per year.

How often does FluoroPharma Medical pay dividends?

The dividend cannot currently be calculated for FluoroPharma Medical or the company does not pay out a dividend.

What is the FluoroPharma Medical ISIN?

The ISIN of FluoroPharma Medical is US3438701019.

What is the FluoroPharma Medical ticker?

The ticker of FluoroPharma Medical is FPMI.

How much dividend does FluoroPharma Medical pay?

Over the past 12 months, FluoroPharma Medical paid a dividend of . This corresponds to a dividend yield of about . For the coming 12 months, FluoroPharma Medical is expected to pay a dividend of 0 USD.

What is the dividend yield of FluoroPharma Medical?

The current dividend yield of FluoroPharma Medical is .

When does FluoroPharma Medical pay dividends?

FluoroPharma Medical pays a quarterly dividend. This is distributed in the months of .

How secure is the dividend of FluoroPharma Medical?

FluoroPharma Medical paid dividends every year for the past 0 years.

What is the dividend of FluoroPharma Medical?

For the upcoming 12 months, dividends amounting to 0 USD are expected. This corresponds to a dividend yield of 0 %.

In which sector is FluoroPharma Medical located?

FluoroPharma Medical is assigned to the 'Health' sector.

Wann musste ich die Aktien von FluoroPharma Medical kaufen, um die vorherige Dividende zu erhalten?

To receive the latest dividend of FluoroPharma Medical from 11/16/2024 amounting to 0 USD, you needed to have the stock in your portfolio before the ex-date on 11/16/2024.

When did FluoroPharma Medical pay the last dividend?

The last dividend was paid out on 11/16/2024.

What was the dividend of FluoroPharma Medical in the year 2023?

In the year 2023, FluoroPharma Medical distributed 0 USD as dividends.

In which currency does FluoroPharma Medical pay out the dividend?

The dividends of FluoroPharma Medical are distributed in USD.

All fundamentals about FluoroPharma Medical

Our stock analysis for FluoroPharma Medical Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of FluoroPharma Medical Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.